Compare Ascendis Pharma A/S (ASND) vs Home Depot Inc (HD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Home Depot Inc — how do they compare? Ascendis Pharma A/S trades at $265.85 (market cap $17.74B), while Home Depot Inc trades at $343.65 (market cap $342.31B). The key difference: Home Depot Inc is far larger — about 19.3× Ascendis Pharma A/S's market cap, and Home Depot Inc pays a 2.71% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | HD | |
|---|---|---|
Market Cap | $17.74B | $342.31B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $423.42 |
52-Week Low | $163.32 | $297.51 |
Enterprise Value | $18.11B | $403.87B |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Home Depot (HD) trades at $343.65, up 0.1% on the day, with mixed technical signals showing a bearish overall trend but bullish moving averages. The stock's valuation metrics include a P/E of 24.38 and P/S of 2.05, with revenue reaching $159.51 billion in 2025 and net income of $14.81 billion. Recent earnings show beats in Q4 2025 and Q1 2026 but a miss in Q3 2025, while cash flow trends indicate operational strength despite a net outflow of $2.10 billion in 2025.
The outlook remains supported by analyst consensus with a $370.59 price target and 59% buy ratings, though risks include weakening big-ticket demand and margin pressures from investments. Housing market volatility and rising mortgage rates pose headwinds, but Pro customer growth and digital initiatives offer resilience for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →
